Literature DB >> 28887601

Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?

Daniel Bulzico1,2, Paulo Antônio Silvestre de Faria3, Camila Bravo Maia3, Marcela Pessoa de Paula4, Davi Coe Torres5, Gerson Moura Ferreira6, Bruno Ricardo Barreto Pires6, Rocio Hassan5, Eliana Abdelhay6, Mario Vaisman7, Leonardo Vieira Neto4,7.   

Abstract

PURPOSE: Epithelial-mesenchymal transition (EMT) is a biological dynamic process by which epithelial cells lose their epithelial phenotype and acquire mesenchymal invasive and migratory characteristics. This has been postulated as an essential step during cancer progression and metastasis. Although this is well described in other tumors, the role of EMT in adrenocortical tumors (ACT) has yet to be addressed.
METHODS: The aim of this study was to evaluate the expression of EMT markers e-cadherin, vimentin, and fibronectin, along with EMT-transcription factors (EMT-TFs), TWIST1, SIP1, and SNAIL in 24 adrenocortical carcinoma (ACC), 19 adrenocortical adenomas (ACA), 27 childhood-onset adrenocortical tumors (CAT), and 12 normal adrenal glands. The association of EMT and EMT-TFs with clinical outcomes and pathology features were also evaluated.
RESULTS: Cytoplasmic vimentin expression was increased among CAT samples when compared to ACC, ACA, and normal adrenal samples (p < 0.001). There was no difference in e-cadherin and fibronectin expression observed between groups. Nuclear and cytoplasmic expression of TWIST1 and SIP1 was stronger in CAT and ACC vs. ACA and normal tissue samples (all, p < 0.05). ACT, regardless of classification, exhibited increased SNAIL expression when compared to normal tissue (p < 0.05). A significant correlation was observed between vimentin and TWIST1 (r s = 0.44, p < 0.001); SIP1 (r s = 0.51, p < 0.001); and SNAIL (r s = 0.23, p < 0.05). TWIST1 and SIP1 expressions demonstrated a significant correlation (r s = 0.56, p < 0.001). High SIP1 expression was associated with a lower survival rate among ACC cases (p < 0.05).
CONCLUSIONS: Vimentin, TWIST1, and SIP1 expressions are increased in aggressive ACT. Therefore, EMT may play a relevant role in adrenal tumorigenesis.

Entities:  

Keywords:  Adenoma; Adrenal cortex; Carcinoma; Immunohistochemistry

Mesh:

Substances:

Year:  2017        PMID: 28887601     DOI: 10.1007/s12020-017-1409-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  62 in total

Review 1.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

Review 2.  An overview of epithelio-mesenchymal transformation.

Authors:  E D Hay
Journal:  Acta Anat (Basel)       Date:  1995

3.  Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience.

Authors:  Abdurrahman Comlekci; Serkan Yener; Senem Ertilav; Mustafa Secil; Baris Akinci; Tevfik Demir; Levent Kebapcilar; Firat Bayraktar; Sena Yesil; Sevinc Eraslan
Journal:  Endocrine       Date:  2009-10-30       Impact factor: 3.633

Review 4.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

Review 5.  Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.

Authors:  Hua Sui; Lei Zhu; Wanli Deng; Qi Li
Journal:  Oncol Res Treat       Date:  2014-09-16       Impact factor: 2.825

6.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.

Authors:  Frédérique Tissier; Catherine Cavard; Lionel Groussin; Karine Perlemoine; Gwladys Fumey; Anne-Marie Hagneré; Fernande René-Corail; Eric Jullian; Christine Gicquel; Xavier Bertagna; Marie-Cécile Vacher-Lavenu; Christine Perret; Jérôme Bertherat
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 7.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

8.  Twist predicts poor outcome of patients with astrocytic glioma.

Authors:  Kristiina Nordfors; Joonas Haapasalo; Katri Mäkelä; Kirsi J Granberg; Matti Nykter; Miikka Korja; Timo Paavonen; Hannu Haapasalo; Ylermi Soini
Journal:  J Clin Pathol       Date:  2015-07-10       Impact factor: 3.411

9.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.

Authors:  M Reincke; M Karl; W H Travis; G Mastorakos; B Allolio; H M Linehan; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.

Authors:  Aude Salomon; Michelle Keramidas; Cécile Maisin; Michaël Thomas
Journal:  Oncotarget       Date:  2015-05-10
View more
  4 in total

1.  Targeted Disruption of Lats1 and Lats2 in Mice Impairs Adrenal Cortex Development and Alters Adrenocortical Cell Fate.

Authors:  Amélie Ménard; Nour Abou Nader; Adrien Levasseur; Guillaume St-Jean; Marie Le Gad- Le Roy; Derek Boerboom; Marie-Odile Benoit-Biancamano; Alexandre Boyer
Journal:  Endocrinology       Date:  2020-05-01       Impact factor: 4.736

2.  Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells.

Authors:  Bruno R B Pires; Renata Binato; Gerson M Ferreira; Stephany Corrêa; Bárbara Du Rocher; Daniel Bulzico; Susanne Crocamo; Everton Cruz Dos Santos; Luize G Lima; Eliana Abdelhay
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

3.  Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.

Authors:  Dipranjan Laha; Robert R C Grant; Prachi Mishra; Myriem Boufraqech; Min Shen; Ya-Qin Zhang; Matthew D Hall; Martha Quezado; Michelly Sampaio De Melo; Jaydira Del Rivero; Martha Zeiger; Naris Nilubol
Journal:  J Exp Clin Cancer Res       Date:  2022-09-23

4.  Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.

Authors:  Jiayu Liang; Zhihong Liu; Xin Wei; Liang Zhou; Yongquan Tang; Chuan Zhou; Kan Wu; Fuxun Zhang; Fan Zhang; Yiping Lu; Yuchun Zhu
Journal:  BMC Cancer       Date:  2019-11-29       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.